Startups
Edit
Graybug Vision
http://graybug.studio1440staging3.com/Last activity: 20.08.2019
Probably Closed
Graybug Vision is developing products to reduce the frequency of dosing for ocular therapies using its injectable controlled release technologies. Their lead product, GB-102, has been demonstrated to provide a therapeutic levels of sunitinib (a VEGFR/PDGFR dual inhibitor) in preclinical studies. With this dual inhibition and reduced dosing frequency, GB-102, has the potential to become a best in class therapy for the treatment of nAMD
Overview
Total raised
$80M
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 1
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
Reviews 0
FAQ about Graybug Vision
How much funding has Graybug Vision raised?
Graybug Vision has raised $80M in total across 1 funding round.
Is Graybug Vision still active?
Graybug Vision is probably closed: its latest activity on Parsers VC dates from Aug 20, 2019.